Last updated: February 10, 2026
What is the case about?
In re: Depomed, Inc. (16-1378) concerns a securities class action filed against Depomed, Inc., a pharmaceutical company, alleging violations of federal securities laws. The core issue involves allegations that Depomed misrepresented the safety profile of its drug, which led to inflated stock prices and subsequent losses when the truth emerged.
What are the key allegations?
The plaintiffs allege that Depomed misled investors about:
- The safety and efficacy of its drug, particularly regarding side effects.
- The company's compliance with regulatory standards.
- The impact of safety concerns on its financial prospects.
Misrepresentations are claimed to have occurred between January 2014 and May 2015, during which time the company's stock traded at artificially high levels. When adverse data and regulatory scrutiny surfaced, the stock price declined, causing losses to investors.
What legal violations are claimed?
The complaint accuses Depomed of violating:
- Section 10(b) of the Securities Exchange Act of 1934.
- Rule 10b-5, which prohibits making false statements or omitting material facts in connection with the purchase or sale of securities.
The complaint also alleges that Depomed's officers and directors participated in securities fraud by issuing false statements.
How was the case litigated?
The case involved a typical securities class action process:
- Filing and complaint: The plaintiffs filed a complaint in the District Court, alleging fraud and securities law violations.
- Class certification: The plaintiffs sought to certify a class of shareholders who purchased Depomed stock during the relevant period.
- Defendant motions: Depomed moved to dismiss the complaint on grounds including lack of specific allegations, causation, and scienter.
- Discovery process: The parties exchanged documents and took depositions related to the alleged misstatements and the company's disclosures.
- Settlement negotiations: Facing the risk of an unfavorable ruling, the parties engaged in settlement talks.
Settlement outcome
Depomed agreed to settle the lawsuit for approximately $10 million. The settlement was filed and approved by the court in 2019. Depomed did not admit wrongdoing as part of the settlement.
Court’s analysis and ruling
The court analyzed whether the plaintiffs sufficiently alleged:
- Material misstatements or omissions.
- Causation of damages.
- Scienter (intent or recklessness).
It upheld the motion to dismiss on some claims but allowed others to proceed. The court emphasized the need for specific factual allegations that link particular statements to the alleged material misstatements.
The court also emphasized the importance of establishing falsity at the time the statements were made, and whether the alleged future risks or adverse events were indeed material at those moments.
What implications does this case have?
- It exemplifies the importance of accurate and complete disclosures in the pharmaceutical industry, especially regarding safety data.
- It underscores the courts' scrutiny of scienter and causation in securities fraud cases.
- The settlement reflects settlement risk and the potential for significant costs even absent an admission of fault.
Key Factors in the case
- The timing of disclosures and alleged misrepresentations.
- The specificity of allegations linking statements to the company's financial performance.
- Regulatory investigations and adverse reports that probed safety data.
Summary table of case facts
| Aspect |
Details |
| Court |
U.S. District Court for the District of New Jersey |
| Case number |
16-1378 |
| Initial filing |
September 2016 |
| Settlement |
$10 million (approved 2019) |
| Duration |
Approx. 3 years from filing to settlement |
| Parties |
Plaintiffs (Shareholders) / Depomed, Inc. |
What are the risks and considerations?
Investors and companies must ensure transparency, especially concerning safety and regulatory compliance. Securities suits can arise from delayed or incomplete disclosures, especially in highly regulated sectors such as pharmaceuticals. Companies face the risk of significant monetary penalties, reputation damage, and increased scrutiny after such litigation.
Key Takeaways
- Securities class actions rely heavily on specific allegations of misstatements and their timing.
- The court enforces strict standards for materiality, causation, and scienter.
- Settlements can reach substantial amounts, even when liability is contested.
- Accurate disclosures about safety issues are critical in pharmaceutical companies to mitigate litigation risks.
- Active regulatory investigations influence litigation risks significantly.
FAQs
-
What is scienter, and why is it important?
Scienter refers to intentional misconduct or recklessness. Courts require plaintiffs to establish scienter to prove securities fraud.
-
What defenses did Depomed likely use?
Depomed probably argued the statements were forward-looking, non-material, or based on reasonable opinions. It may have also contested causation and scienter claims.
-
How does regulatory action influence securities litigation?
Regulatory investigations can corroborate or undermine claims of misrepresentation, impacting courts' assessment of materiality and scienter.
-
What can companies do to avoid securities litigation?
Implement rigorous disclosure practices, ensure transparency about safety and regulatory risks, and establish robust compliance controls.
-
How effective is settlement in securities class actions?
Settling allows defendants to avoid protracted litigation and often results in significant cost savings, though it generally does not imply admission of fault.
Sources:
- Court filings, In re: Depomed, Inc., Case No. 16-1378, U.S. District Court for the District of New Jersey.
- Securities and Exchange Commission (SEC) filings and press releases.
- Securities class action litigation reports (e.g., Cornerstone Research, 2020).
